Inventor · disambiguated record
Ginger Rakestraw
Also filed as: RAKESTRAW GINGER C · RAKESTRAW GINGER CHAO · RAKESTRAW Ginger
34 granted patents·9 pending applications·344 citations·filing 2011–2024
97Inventor score
Files withBRISTOL MYERS SQUIBB CO35FIVE PRIME THERAPEUTICS INC6CAMPHAUSEN RAY1JUNO THERAPEUTICS INC1
Top patents by PatentIndex Score
43 records- 0197US9662373B2Fibronectin based scaffold domain proteins that bind to myostatinBRISTOL MYERS SQUIBB CO·Filed 2015·Granted May 30, 2017·27 cites·31 claims
- 0297US8420098B2Fibronectin based scaffold domain proteins that bind to PCSK9CAMPHAUSEN RAY·Filed 2011·Granted Apr 16, 2013·86 cites·8 claims
- 0396US11926673B2Antagonistic CD40 monoclonal antibodies and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2022·Granted Mar 12, 2024·4 cites·18 claims
- 0496US11254750B2Antagonistic CD40 monoclonal antibodies and uses in treating immune responsesBRISTOL MYERS SQUIBB CO·Filed 2020·Granted Feb 22, 2022·6 cites·25 claims
- 0596US9771411B2Method of treating cancer by administering EGFR and EGFR/IGFIR binding moleculesBRISTOL MYERS SQUIBB CO·Filed 2015·Granted Sep 26, 2017·22 cites·20 claims
- 0696US9017655B2Bispecific EGFR/IGFIR binding moleculesBRISTOL MYERS SQUIBB CO·Filed 2012·Granted Apr 28, 2015·36 cites·10 claims
- 0796US8933199B2Fibronectin based scaffold domain proteins that bind to myostatinBRISTOL MYERS SQUIBB CO·Filed 2013·Granted Jan 13, 2015·36 cites·36 claims
- 0896US8853154B2Fibronectin based scaffold domain proteins that bind to myostatinBRISTOL MYERS SQUIBB CO·Filed 2013·Granted Oct 7, 2014·35 cites·15 claims
- 0995US8993265B2Fibronectin based scaffold domain proteins that bind to myostatinBRISTOL MYERS SQUIBB CO·Filed 2014·Granted Mar 31, 2015·27 cites·11 claims
- 1094US12419953B2Methods of treatment or prevention of immune responses and inflammatory diseases with antagonistic CD40 monoclonal antibodiesBRISTOL MYERS SQUIBB CO·Filed 2024·Granted Sep 23, 2025·1 cites·20 claims
- 1194US11795231B2Antagonistic CD40 monoclonal antibodies and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2022·Granted Oct 24, 2023·2 cites·23 claims
- 1294US11773178B2Antagonistic CD40 monoclonal antibodies and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2022·Granted Oct 3, 2023·2 cites·17 claims
- 1393US9493546B2Fibronectin based scaffold domain proteins that bind to myostatinBRISTOL MYERS SQUIBB CO·Filed 2014·Granted Nov 15, 2016·14 cites·20 claims
- 1492US9856309B2Fibronectin based scaffold domain proteins that bind PCSK9BRISTOL MYERS SQUIBB CO·Filed 2015·Granted Jan 2, 2018·10 cites·16 claims
- 1591US10947297B2Fibronectin based scaffold domain proteins that bind PCSK9BRISTOL MYERS SQUIBB CO·Filed 2017·Granted Mar 16, 2021·5 cites·19 claims
- 1691US10183987B2Polynucleotides encoding bispecific EGFR/IGF-IR binding moleculesBRISTOL MYERS SQUIBB CO·Filed 2017·Granted Jan 22, 2019·7 cites·13 claims
- 1790US12077584B2Methods of treating HLA-E-expressing cancers by administering antibodies which bind human natural killer cell inhibitory receptor group 2A (NKG2A)BRISTOL MYERS SQUIBB CO·Filed 2022·Granted Sep 3, 2024·1 cites·76 claims
- 1890US10954286B2Bispecific EGFR/IGFIR binding moleculesBRISTOL MYERS SQUIBB CO·Filed 2018·Granted Mar 23, 2021·2 cites·20 claims
- 1990US9234027B2Fibronectin based scaffold domain proteins that bind PCSK9BRISTOL MYERS SQUIBB CO·Filed 2013·Granted Jan 12, 2016·10 cites·22 claims
- 2088US11274150B2Anti-human natural killer cell inhibitory receptor group 2A protein (NKG2A) antibodiesBRISTOL MYERS SQUIBB CO·Filed 2019·Granted Mar 15, 2022·2 cites·113 claims
- 2187US2024316161A1Fibronectin based scaffold domain proteins that bind to myostatinBRISTOL MYERS SQUIBB CO·Filed 2023·Application pending·0 cites
- 2286US12409223B2Antagonistic CD40 monoclonal antibodies and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2023·Granted Sep 9, 2025·0 cites·18 claims
- 2386US2024239870A1Fibronectin based scaffold domain proteins that bind pcsk9BRISTOL MYERS SQUIBB CO·Filed 2023·Application pending·0 cites
- 2485US11261258B2Antagonistic CD40 monoclonal antibodies and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2019·Granted Mar 1, 2022·2 cites·14 claims
- 2583US10406212B2Fibronectin based scaffold domain proteins that bind to myostatinBRISTOL MYERS SQUIBB CO·Filed 2017·Granted Sep 10, 2019·2 cites·11 claims
- 2683US2025101100A1Anti-nkg2a antibodies and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2024·Application pending·0 cites
- 2781US2025206822A1Antibodies Binding to Vista at Acidic pHFIVE PRIME THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 2879US12195535B2Antibodies binding to VISTA at acidic pHFIVE PRIME THERAPEUTICS INC·Filed 2023·Granted Jan 14, 2025·0 cites·37 claims
- 2978US11981734B2Nucleic acid molecules encoding antibodies which bind natural killer cell inhibitory receptor group 2A protein (NKG2A)BRISTOL MYERS SQUIBB CO·Filed 2022·Granted May 14, 2024·0 cites·163 claims
- 3078US10245302B2Fibronectin based scaffold domain proteins that bind to myostatinBRISTOL MYERS SQUIBB CO·Filed 2016·Granted Apr 2, 2019·1 cites·17 claims
- 3177US12173069B2Antibodies binding to vista at acidic pHFIVE PRIME THERAPEUTICS INC·Filed 2019·Granted Dec 24, 2024·1 cites·28 claims
- 3277US11813315B2Fibronectin based scaffold domain proteins that bind to myostatinBRISTOL MYERS SQUIBB CO·Filed 2019·Granted Nov 14, 2023·0 cites·20 claims
- 3376US11858979B2Fibronectin based scaffold domain proteins that bind PCSK9BRISTOL MYERS SQUIBB CO·Filed 2021·Granted Jan 2, 2024·0 cites·10 claims
- 3476US11708405B2IP-10 antibodies and their usesBRISTOL MYERS SQUIBB CO·Filed 2019·Granted Jul 25, 2023·1 cites·21 claims
- 3575US10556948B2IP-10 antibodies and their usesBRISTOL MYERS SQUIBB CO·Filed 2016·Granted Feb 11, 2020·2 cites·19 claims
- 3675US2025129166A1Antibodies Binding to Vista at Acidic pHFIVE PRIME THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 3763US11603406B2Antibodies binding to VISTA at acidic pHFIVE PRIME THERAPEUTICS INC·Filed 2018·Granted Mar 14, 2023·0 cites·39 claims
- 3861US2025161359A1Proteinase 3 (pr3) chimeric autoantibody receptor t cells and related methods and usesJUNO THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 3952US12091462B2Antibodies binding to vista at acidic pHFIVE PRIME THERAPEUTICS INC·Filed 2019·Granted Sep 17, 2024·0 cites·20 claims
- 4052US12065505B2Antibodies and antigen binding peptides for factor XIa inhibitors and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2022·Granted Aug 20, 2024·0 cites·18 claims
- 4150US2022332817A1Antibodies against human trem-1 and uses thereofBRISTOL MYERS SQUIBB CO·Filed 2020·Application pending·0 cites
- 4246US2021395392A1Anti-mertk antibodies for treating cancerBRISTOL MYERS SQUIBB CO·Filed 2019·Application pending·0 cites
- 4342US2017326249A1Antibody-drug conjugate of an anti-glypican-3 antibody and a tubulysin analog, preparation and usesBRISTOL MYERS SQUIBB CO·Filed 2017·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Ginger Rakestraw files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →